TD Cowen initiated coverage of Standard BioTools with a Buy rating and $3.50 price target.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LAB:
- Standard BioTools announces new solutions for Imaging Mass Cytometry workflow
- Standard BioTools Introduces New High-Throughput Multiplexed Whole Slide Imaging Modalities Set to Redefine the boundaries of Tissue Imaging
- Standard BioTools initiated with a Buy at Jefferies
- Standard BioTools Announces Multi-Year Strategic Engagement with Bristol Myers Squibb for Use of the SomaScan® Platform for Translational Medicine Research
- Standard BioTools announces multi-year agreement with Bristol Myers